JOHNSON & JOHNSON (JNJ) Form 10-Q — Oct 21, 2026
Johnson & Johnson reported Q3 2026 sales of $25.4 billion, up 5.9% year over year, but net earnings collapsed to $210 million ($0.09 diluted EPS) from $5.15 billion ($2.12) a year earlier. The earnings plunge was driven by a $5.5 billion charge for a proposed talc ovarian litigation resolution — conditioned on at least 95% claimant participation — plus a $1.0 billion IPR&D charge from the Firefly Bio acquisition, bringing the total talc reserve to roughly $9.0 billion. Underlying operations remain strong: nine-month sales grew 7.4% to $74.8 billion with operating cash flow of $18.9 billion, and Oncology grew 16.8% operationally, offsetting a ~4.7% drag from STELARA biosimilar erosion.
Key figures
- Eps
- 0.09
- Eps Beat
- 0
- Revenue
- 25399000000
- Net Income
- 210000000
- Total Debt
- 44600000000
- Revenue Yoy
- 5.9% (Q3); 7.4% nine months ($74,771M vs $69,629M)
- Cash Position
- 16910000000
- Shares Outstanding
- 2407310266
- Net debt
- $27.4 billion
- Talc plaintiffs
- approximately 76,500
- Dividend per share
- $1.34 quarterly
- Talc total reserve
- approximately $9.0 billion (about half current liability)
- Nine month diluted eps
- 4.49
- Talc litigation charge
- $5.5 billion (proposed ovarian litigation resolution)
- Firefly bio iprd charge
- approximately $1.0 billion
- Precardia iprd impairment
- approximately $0.4 billion
- Q3 prior year diluted eps
- 2.12
- Effective tax rate nine months
- 14.0% vs 21.5%
- Stelara operational sales drag
- approximately 4.2% (Q3 worldwide)
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.